Von Hippel-Lindau Disease - Von Hippel-Lindau Disease...Figure 3. VHL disease associated renal cell carcinomas are of clear cell type (H&E stain). PHEOCHROMOCYTOMAS IN VHL SYNDROME

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.

Von Hippel-Lindau DiseaseSven Gläsker, MDProfessor, Department of Neurosurgery, VUB University Hospital Brussels, [email protected] author.

Hartmut P.H. Neumann, MDProfessor, Department of Internal Medicine, Freiburg University Medical Center, [email protected]

Christian A. Koch, MD, FACP, MACEProfessor, Department of Internal Medicine, University of Louisville, KY; Oldenburg University and Medicover MVZ, [email protected]

Alexander Vortmeyer, MDProfessor and Director, Neuropathology Training Program, Department of Pathology, Indiana University School of Medicine, Indianapolis, [email protected]

Created: September 12, 2018.

ABSTRACTVon Hippel-Lindau (VHL) disease is an autosomal dominantly inherited tumor syndrome. The incidence of VHL disease is about one in36,000 livebirths and the penetrance is higher than 90%. Similar to other tumor suppressor gene disorders, VHL disease is characterizedby frequent development of specific types of tumors in selective organs. The disease is named after the German ophthalmologist Eugenvon Hippel, who identified and described characteristic retinal manifestations, and the Swedish pathologist Arvid Lindau, whodiscovered the frequent co-occurrence of retinal and cerebellar hemangioblastoma with tumors and cysts in visceral organs. Hedescribed the clinical spectrum of VHL disease in detail in a large series of cases from Sweden but also from other European countries.A clinical classification system divides individuals who are affected by VHL disease into two groups: Those predominantly withoutpheochromocytoma are classified as VHL type 1, and those predominantly with pheochromocytoma are classified as VHL type 2. VHLtype 2 is further subdivided into type 2A (with renal cancer) and type 2B (without renal cancer). In type 2C affected patients developsolely pheochromocytomas. Tumorigenesis in patients with VHL disease shares fundamental principles in the different affected organsystems: germline VHL inactivation leads to persistence of microscopic developmentally arrested structures. These microscopic cellclusters already reveal biallelic VHL inactivation and consequent up-regulation of hypoxia inducible factor (HIF) and down-streamtargets like VEGF, EPO. Current research for pharmacotherapy of VHL disease targets proteins of the HIF cascade and compounds thatlead to upregulation and re-functionalization of mutated VHL protein. For complete coverage of all related areas of Endocrinology,please visit our on-line FREE web-text, WWW.ENDOTEXT.ORG.

INTRODUCTIONVon Hippel-Lindau (VHL) disease is an autosomal dominantly inherited tumor syndrome. The incidence of VHL disease is about one in36,000 livebirths [1, 2] and the penetrance is higher than 90% [3]. Similar to other tumor suppressor gene disorders, VHL disease ischaracterized by frequent development of specific types of tumors in selective organs.

The disease is named after the German ophthalmologist Eugen von Hippel, who identified and described characteristic retinalmanifestations [4], and the Swedish pathologist Arvid Lindau, who discovered the frequent co-occurrence of retinal and cerebellarhemangioblastoma with tumors and cysts in visceral organs. He described the clinical spectrum of VHL disease in detail in a large seriesof cases from Sweden but also from other European countries [5, 6].

A clinical classification system divides individuals who are affected by VHL disease into two groups [7]: Those predominantly withoutpheochromocytoma are classified as VHL type 1, and those predominantly with pheochromocytoma are classified as VHL type 2. VHLtype 2 is further subdivided into type 2A (with renal cancer) and type 2B (without renal cancer). In type 2C affected patients developsolely pheochromocytomas [8].

VON HIPPEL-LINDAU DISEASE MANIFESTATIONSVHL disease targets a highly selective subset of organs by the frequent development of specific types of heavily vascularized tumors.Multiple and bilateral tumors occur frequently. Affected organs and tumors are listed in table 1 [9-12].

Table 1:

Manifestations of VHL disease [9-12]

Von Hippel-Lindau Disease - Endotext - NCBI Bookshelf https://www.ncbi.nlm.nih.gov/books/NBK279124/?report=...

1 of 18 2/11/19, 8:44 AM

Tumor Frequency Mean age of onset

Retinal hemangioblastomas 60% 25y

Cerebellar and spinal hemangioblastomas 65% 33y

Endolymphatic sac tumors 10% 22y

Renal clear cell carcinomas and cysts 45% 39y

Pheochromocytomas 20% 30y

Pancreatic cysts, microcystic serous adenomas, neuroendocrine tumors 35-70% 36y

Epididymal and broad ligament cystadenomas > 50% of male unknown

CNS HEMANGIOBLASTOMAS IN VHL SYNDROMEHemangioblastomas are the index tumors of VHL disease and are frequently the earliest manifestation of the disease. Multiplehemangioblastomas occur frequently in patients with VHL disease. In one major study 127 of 160 patients with VHL-associatedhemangioblastomas had multiple tumors [13]. The central nervous system hemangioblastoma burden in VHL disease is associated withpartial germline deletions and male sex [14]. The benign slow growing highly vascularized tumors cause neurologic symptomsdepending on their size and location [13, 14]. A spinal hemangioblastoma may lead to focal neurologic deficits such as weakness andparesthesias. Posterior fossa tumors may present with ataxia, dysmetria, nystagmus, and slurred speech. Symptoms may also evolve dueto CSF obstruction causing signs of increased intracranial pressure or brain stem herniation [3, 11, 15]. Symptoms are usually not causedby the tumor itself but rather by an associated pseudocyst or syrinx, which is caused by vascular leakage from the tumor [16] and whichis usually larger than the tumor itself [13]. Polyglobulia has been reported in patients with hemangioblastomas [17]. It occurs in 10% ofpatients [18] and may cause thrombosis. Removal of the largest hemangioblastoma usually resolves polyglobulia [18].

Diagnosis is established by contrast enhanced MRI of the head and spine [19, 20], which typically identifies a solid enhancing noduleassociated with a pseudocyst or syrinx (figure 1).

Figure 1:

On contrast-enhanced MRI, hemangioblastoma is identified as solid enhancing nodule; the tumor is typically associated with extra-tumoral cyst (left) or syrinx (right).

Patients with VHL disease frequently develop several CNS hemangioblastomas but not all of the tumors need to be removed. Surgery isneeded for all symptomatic tumors and for all tumors causing CSF obstruction [13, 21, 22]. Once symptoms occur, they can usually notbe reversed by surgery; therefore, surgery may be recommended in a subset of asymptomatic tumors with radiographic progression [22].Complete surgical removal of the solid tumor is the treatment of choice. If surgery is not possible, radiation therapy may be analternative. [23-27]. There is currently no established chemotherapy for hemangioblastomas. Substances studied include different


2 of 18 2/11/19, 8:44 AM

tyrosine kinase inhibitors such as semaxanib [28-32], Vatalanib (ongoing trial), Sunitinib [33-36] and Dovitinib [37] as well aspazopanib [38-40]

Surgical resection of hemangioblastomas requires careful dissection in the plane between tumor and CNS tissue. If the tumor is entered,major bleeding will occur. Hemangioblastoma patients harbor a risk for spontaneous or perioperative hemorrhage [41] and preoperativeembolization has been recommended for large solid tumors [42, 43]. The tumors can usually be completely removed and permanent newneurologic deficit due to surgery is rare in experienced hands. Intraoperative ultrasound allows for identification of small tumors andcontrol of complete resection of the tumors [44].

Recently intraoperative ICG angiography has been used by different groups. Some of them find it helpful in understanding the vascularanatomy of the lesions, whereas others find it of limited value [45-50]

Hemangioblastomas are composed of a dense capillary network with “stromal” cells in between. Microdissection and genetic deletionanalysis revealed the “stromal” cells to represent the neoplastic component of these tumors [51], while the capillary networkpredominantly represents reactive VEGF-driven angiogenesis. The histogenesis of the neoplastic “stromal” cells has been controversial.Tumor cells stain consistently positive for neuron specific enolase [52-54], neural cell adhesion molecule [55, 56] and vimentin [54-58].The “stromal” cells appears to represent developmentally arrested VHL-deficient hemangioblast progenitor cells with hematopoieticdifferentiation potential [59-63], based on the observation of expression of pre-hemangioblastic markers like scl and brachyury [63-66]and the ability of primitive blood island formation and differentiation into early red blood cells [65, 67-69]. Furthermore, anatomicstudies on spinal cord and cerebellum of VHL patients revealed numerous developmentally arrested structural elements [70] that serveas potential precursor material for hemangioblastic tumors [71]. In addition to hematopoietic differentiation capacity the tumor cells arealso capable of primitive vasculogenesis[72, 73]. It has remained unresolved, however, whether the tumor cells are of mesodermal orneuroectodermal origin.

RETINAL HEMANGIOBLASTOMAS IN VHL SYNDROMERetinal hemangioblastomas are benign tumors that can occur as a sporadic entity as well as in patients with VHL disease. Tumorsfrequently occur in multiplicity and bilaterally (in about 50%). Histologically, retinal hemangioblastomas are identical to CNShemangioblastomas [74]. High expression of VEGF in these tumors causes vascularization, vascular leakage and exudation, andeventually retinal detachment in the eye.

Annual fundoscopic screening and early treatment of asymptomatic lesions is recommended for VHL patients starting at one year ofage. Most peripheral retinal hemangioblastomas are well controlled by laser photocoagulation or cryotherapy [75, 76]. Vitrectomy maybe performed in larger tumors [77]. Tumors in the optic disc should be monitored without treatment. Alternative treatments are inexperimental stages and include VEGF inhibition [30, 78, 79] and radiation therapy [80]. Recently propranolol has been suggested fortreatment of retinal hemangioblastomas [81].

With screening and early treatment of detected lesions, visual prognosis for VHL patients is good: In one major study approximately 8%of the eyes of VHL patients had poor visual acuity of 20/200 or worse with approx. 8% of these eyes requiring enucleation [82].Genotyping of young patients presenting with paraganglioma or pheochromocytoma can lead to early detection of retinalhemangioblastomas and other VHL manifestations in family members [83].


3 of 18 2/11/19, 8:44 AM

Figure 2:

Fundoscopic photograph illustrating a retinal hemangioblastoma (arrows).

RENAL MANIFESTATIONS IN VHL SYNDROMEPatients with VHL disease can develop renal cysts and renal cell carcinomas [84-89]. Renal cell carcinomas are malignant tumors. Thepathogenetic relationship between renal cysts and renal cell carcinoma has remained unclear. One study suggests rare transition from acyst to a solid lesion [90]. Histologically, renal cell carcinomas in VHL disease are always of clear-cell type (figure 3), and smallcarcinomas tend to be low grade [91]. While small renal tumors in VHL disease tend to be low grade and minimally invasive [91], theirrate of growth varies widely [92, 93].

Renal manifestations are usually multiple and bilateral in patients with VHL disease. They remain asymptomatic for a long time.Advanced cases of renal cell carcinoma may present with hematuria, flank pain, or a flank mass.

Renal cysts in VHL disease usually do not require treatment. Therapy of renal cell carcinoma is targeted towards prevention ofmetastasis and preservation of kidney function. In contrast to sporadic renal cell carcinoma, nephrectomy is not recommended asprimary therapy for VHL-disease-associated renal cell carcinomas. Most specialized centers recommend nephron-sparing surgery forcarcinomas that exceed 3 cm in size [85, 94]. Recent work supports the hypothesis, that a diameter of 4 cm is also acceptable [95].Although the gold standard for treating renal tumors are open and laparoscopic partial nephrectomy, alternative therapies includingcryotherapy and radiofrequency ablation are presently utilized [96]. Possible substances for treatment of metastasized disease includepazopanib [97].


4 of 18 2/11/19, 8:44 AM

Figure 3.

VHL disease associated renal cell carcinomas are of clear cell type (H&E stain).

PHEOCHROMOCYTOMAS IN VHL SYNDROMEPheochromocytomas usually are sporadic but in more than 33% of patients can occur in a familial syndrome such as the VHL syndrome[98, 99]. Presence of pheochromocytomas defines VHL disease type 2 (A,B,C) (Figure 4, modified from [100]).

Figure 4.

VHL-associated pheochromocytoma

In a series of 246 patients with VHL syndrome, 64 patients (26%) were found to have a pheochromocytoma [101]. In one third, thesetumors were “nonfunctional” and did not cause symptoms of catecholamine excess such as hypertension. Utilizing 18F-DOPAfunctional imaging in 52 patients with von Hippel-Lindau disease, 4 of 10 patients with positive adrenal uptake had elevatedcatecholamine levels, i.e. 6 of 10 pheochromocytomas were “silent” [102]. Asymptomatic patients with pheochromocytoma have also


5 of 18 2/11/19, 8:44 AM

been reported in 15 of 150 patients seen at the Mayo Clinic [103] and in 19 of 33 patients with adrenal pheochromocytomas that wereincidentally discovered [104]. The mean age at diagnosis of VHL patients reported by Walther et al. 1999 [101] was 29 years with arange from age 6 to age 54 years. Bilateral pheochromocytomas in this group were found in 39% of patients. Extra-adrenalpheochromocytomas or paragangliomas in patients with VHL disease can be sympathetic or parasympathetic and, if located in the headand neck, are mostly unable to produce and secrete catecholamines [99, 105-108]. Genotyping of young patients presenting with afunctional paraganglioma can lead to detection of other family members with VHL disease [83]. Recent studies in Chinese and AsianIndian patients revealed novel genotype-phenotype correlations in VHL disease [109-111]. Loss of the ability of VHL protein to degradeHIF under hypoxic conditions can promote the development of bilateral pheochromocytomas [112].

In general, extra-adrenal pheochromocytomas have a higher frequency and potential of malignancy than pheochromocytomas located inthe adrenal gland [113]. Malignant pheochromocytomas (defined as the presence of chromaffin tissue at locations where such tissueshould not be present, i.e. lungs, liver, bone, lymph nodes) are uncommon in patients with VHL syndrome [92, 99, 100, 114, 115].However, even in children as young as 12 years of age metastatic pheochromocytomas in VHL disease have been observed [116].Unfortunately, there are no markers yet that can reliably distinguish a benign from a malignant pheochromocytoma [117].

The detection of a pheochromocytoma in patients with VHL syndrome is particularly important, given the possible need for surgicalinterventions for other tumors such as CNS hemangioblastomas. Just like in any patient with an undetected pheochromocytoma, surgeryand other factors can lead to life-threatening hypertensive attacks intraoperatively. During pregnancy, surgery usually should take placein the second trimester and may include interval adrenalectomy [118]. Screening for pheochromocytoma in at high risk patients (VHLtype 2A,B,C) should include measurements of urinary catecholamines and fractionated metanephrines, as well as of plasma freemetanephrines, acknowledging that normetanephrine is the predominant biochemical marker for adrenal and extra-adrenal VHL-associated pheochromocytomas, and that methoxytyramine a helpful marker for head and neck paragangliomas [119, 120]. Determiningthe screening age for pheochromocytoma should likely be made dependent on potential beneficial and negative sequelae that couldoccur if screening were not performed, i.e. malignancy (lower than 5% in VHL disease!), hypertension, radiation exposure fromfrequent imaging. There is marked intrafamilial variation, and the penetrance of pheochromocytoma may be as late as age 54 years [101,121]. In a recent study of 37 Danish patients from the national VHL research database and additional international children andadolescents with VHL disease the age range of clinical manifestations (mostly retinal and CNS hemangioblastomas) was from 6 to 17years of age [122].

At present, experts recommend pheochromocytoma screening be started already in childhood at the age of 8 years [99, 123] [9]. Theadrenal glands (suprarenal) can be visualized while undergoing an MRI to look for renal abnormalities in patients with VHL disease.More than 70% of pheochromocytomas presenting in children are due to VHL disease. The diagnosis can further be established byabdominal computed tomography and/or magnetic resonance imaging [9].

Given the low frequency rate of extra-adrenal pheochromocytomas (approx. 15%) and malignant pheochromocytomas (< 5%) inpatients with VHL disease, only selected patients should undergo 123I-MIBG scanning to search for extra-adrenal or metastatic lesions,before operation [113, 124]. Importantly, (isolated) pheochromocytoma can be the presenting manifestation of VHL syndrome [3, 125].Approximately 50% of patients with apparently isolated familial pheochromocytoma have VHL disease and approx. 10% of patientswith apparently sporadic pheochromocytoma [99, 126, 127], acknowledging that a family history is not always present or reliablyobtainable [128] and that even if VHL germline mutations were detected by certified laboratory testing in patients with non-syndromicpheochromocytoma (i.e. in 3 of 182 patients, [129], misdiagnoses can occur.

Treatment of nonmetastatic adrenal pheochromocytoma consists of adrenal sparing (partial) tumor removal, either uni- or bilateral,depending on whether one or both adrenal glands are affected [130-132]. Endoscopic adrenal sparing removal of the pheochromocytomashould be performed in most if not all patients. [133]. Cortical sparing adrenal surgery exhibits < 5% recurrence rates after 10 years offollow-up while preserving normal glucocorticoid function in more than 50% of patients [134]. The perioperative outcome of patientswith VHL disease is very good, although they may have a very high noradrenergic secretion compared to patients withneurofibromatosis type 1 and multiple endocrine neoplasia type 2A [135]. Occasional VHL patients with pheochromocytomas exhibit adecline in tumor size after 19 months of sunitinib therapy [136].

Whether nonfunctional pheochromocytomas (clinically only remarkable as adrenal masses on imaging with normal fractionated urinarymetanephrines and/or normal plasma free metanephrines) require treatment/surgery remains unclear. Important aspects in this contextare the questions how fast such tumors grow, if and when they cause symptoms, and if and when (at what size) they metastasize [137,138].

EPIDIDYMAL CYSTADENOMAS IN VHL SYNDROMEThese non-malignant tumors occur in about half of all male VHL patients [139]. Epididymal cystadenomas consist of cystic andadenomatous areas and arise typically in the caput epididymidis (figure 5). The tumors have been suggested to arise from microscopic


6 of 18 2/11/19, 8:44 AM

precursor structures, which are abundantly observed in the efferent ductiles of the caput epididymidis of VHL patients [140, 141].Epididymal cystadenomas rarely cause symptoms and have no potential for malignant transformation. In rare cases bilateral obstructionof efferent ductiles and spermatic cords may occur resulting in sterility. Epididymal cystadenomas are well visible on ultrasound.

Women who are affected by VHL disease develop cystadenomas of the broad ligaments, which play no major clinical role.

Figure 5.

VHL disease associated epididymal cystadenomas consistently reveal papillary (pap), tubular (tu) and cystic (cy) architecture [140].

PANCREATIC MANIFESTATIONS IN VHL SYNDROMEPancreatic manifestations include pancreatic neuroendocrine tumors, cysts and cystadenomas. Overall, 35–70% of VHL patientsdevelop a pancreatic manifestation [142-144]. Distinguishing between a benign microcystic adenoma and a pancreatic neuroendocrinetumor can be difficult. Similar to hemangioblastomas, pancreatic neuroendocrine tumors reveal a staggering growth pattern [145].

Most pancreatic tumors in VHL disease are asymptomatic. Extremely rare – and depending on size and location – are bile ductobstruction and/or pancreatic insufficiency. Most patients do not need any treatment. This is important for patients with pancreatic cystsand/or microcystic adenomas. In a recent study of 48 patients with VHL disease, branch duct intraductal papillary mucinous neoplasmswere present in 10% [146].

(68)Ga-DOTATOC PET/CT appears to be a very sensitive screening tool in detecting pancreatic neuroendocrine tumors in VHL disease[147]. All patients should be investigated by MRI with intravenous contrast administration. It is very important that imaging isperformed in the early arterial phase. In contrast to the multicystic appearance of microcystic adenoma, neuroendocrine pancreatictumors present as solid lesions and need to be considered for surgical removal. Mutations in exon 3, especially of codons 161/167 are atenhanced risk for metastatic PanNETs [148]. However, most VHL associated pancreatic neuroendocrine tumors are small and slowlygrowing. In general, VHL associated pancreatic neuroendocrine tumors have a favorable prognosis compared to sporadic tumors [149].Tumors with a diameter over 2.8 cm should be treated surgically to avoid metastasis according to a recent multicenter study [148].Resection of pancreatic tumors may also be performed if the patient is undergoing laparotomy for other lesions [150, 151]. In cases ofbiliary obstruction and/or pancreatic insufficiency treatment consists of placing biliary stents and/or replacing pancreatic enzymes. Anew option is organ-sparing endoscopic resection which can be applied to tumors in the tail and the body of the pancreas [152].Chemotherapy is currently under investigation. Occasional patients respond well to somatostatin analog therapy [153].


7 of 18 2/11/19, 8:44 AM

ENDOLYMPHATIC SAC TUMORS IN VHL SYNDROMEEndolymphatic sac tumors are benign cystadenomas that arise in the vestibular aqueduct and may extend into the extraosseous portionof the endolymphatic sac, into the petrous bone, and into the inner ear [154, 155]. Large tumors have been reported to extend into thebrain [50]. The vestibular aqueduct connects the inner ear with the extraosseous portion of the endolymphatic sac, a dural fold at theposterior surface of the petrous bone. Despite their benign nature these lesions grow locally invasive into the temporal bone due to theirorigin in the osseous portion of the vestibular aqueduct.

Patients may present with hypakusis or hearing loss (100%), tinnitus (77%), disequilibrium (62%), and facial paresis (8%) [156].Hearing loss and vestibulopathy may occur suddenly due to tumor-associated intralabyrinthine hemorrhage, or insidiously, consistentwith endolymphatic hydrops [157].

Diagnosis is established by MRI, which shows homogeneous or variable patterns of patchy enhancement and CT (bone window)revealing widening of the osseous portion of the vestibular aqueduct (figure 6).

Radical resection allows for complete excision of the tumors. The preoperative level of hearing can usually be preserved. The timing ofsurgery depends on the severity of symptoms, the slow but variable growth of the tumors, the possibility of injury to the 7 and 8cranial nerves and possible bilateral occurrence. Hearing preserving early surgical resection is recommended to enhance the opportunityfor complete resection and decrease irreversible audiovestibular symptoms [47]. Endolymphatic hydrops can be detected early oncontrast-enhanced delayed FLAIR MRI even before the tumoral mass itself is visible [45]. The role of radiation in the treatment of thesetumors remains controversial (see [50] for a review).

Figure 6.

VHL-associated ELST (endolymphatic sac tumor). MRI reveals an in homogenously enhancing mass in the left temporal bone, CTshows osteolysis.

PROGNOSIS IN VHL SYNDROMEBefore the introduction of clinical screening programs and timely prophylactic treatment of VHL associated lesions, the life expectancyof affected patients used to be impaired with a median survival around 50 years [2, 11]. Nowadays, life expectancy may be significantlyimproved by clinical screening programs with early detection and treatment of VHL manifestations [158]. Modern management of VHLhas meanwhile achieved a life expectancy of additional 10 years [159].

VHL SCREENINGAll patients with hemangioblastoma, the index tumor of VHL disease, should receive a careful family history, screening for detection ofother lesions associated with VHL (table 2), and should undergo genetic testing for VHL disease [160, 161].

Once the diagnosis of VHL disease is established, patients should undergo an annual screening program in order to identifymanifestations early before deficits or metastasis occur. Screening includes periodic contrast enhanced MRI scans. CNS gadoliniumaccumulation will eventually occur in virtually all VHL patients, however, no pathological effect of this accumulation is known so far

th th


8 of 18 2/11/19, 8:44 AM

1.

2.

[47]. The screening programs vary slightly between different centers. An example of a routine surveillance protocol for von Hippel–Lindau disease (modified from Maher [162]) is presented in table 2:

Table 2:

Screening Procedures

Screen for retinal hemangioblastoma: Annual ophthalmic examinations (direct and indirect ophthalmoscopy), beginning at age 1(from birth on).

Screen for CNS hemangioblastoma: Contrast enhanced MRI brain and full spine, beginning at age 12. Annual or biennial dependingon manifestations.

Screen for renal cell carcinoma and pancreatic tumors: MRI (or ultrasound) examinations of the abdomen every 12 months,beginning from the age of 12 years.

Screen for pheochromocytoma: Annual blood pressure monitoring and 24-h urine studies for catecholamine metabolites starting atage 6. Alternatively measuring plasma metanephrines. MRI starting at age 12.

Screen for epididymal cystadenoma: Ultrasonography of the testes starting at 18 years.

Screen for ELST with audiogram: Biennial audiogram starting at age 16

Additional investigations in response to symptoms or signs of specific complications.

MOLECULAR ASPECTS IN VHL SYNDROMEPatients with VHL disease carry a germline mutation of the VHL tumor suppressor gene (VHL). The VHL gene had originally beenlinked to chromosome 3p25 in 1988 [163] and was subsequently cloned in 1993 [164]. The evolutionarily conserved VHL gene encodestwo protein products, a 30-kDa full-length form (p30) and a 19-kDa form (p19).

The protein product of the VHL gene (pVHL) interacts with elongins B, C and Cullin-2 to form the VBC complex, an E3 ubiquitinligase [165]. This multiprotein complex targets proteins for ubiquitin-mediated degradation, analogous to the S. cerevisiae SCF(Skp1/Cdc53/F-box) ubiquitination machinery [166-168]. Major targets of the VBC complex include the regulatory subunits of theheterodimeric transcription factor, hypoxia inducible factor (HIF). Therefore, VHL inactivation causes an up-regulation of HIF anddownstream proteins under normoxic conditions. Many of the HIF targets are involved in the adaptation to acute or chronic hypoxia andinclude genes involved in the uptake and metabolism of glucose (GLUT-1), angiogenesis (VEGF, PDGF), control of extracellular pH(CA9), mitogenesis (TGFα), and erythropoiesis (erythropoietin) [169-172].

In addition to HIF degradation, the VHL protein is involved in HIF-independent cellular processes. It directs the proper deposition offibronectin and collagen IV within the extracellular matrix [173]. Furthermore, it works to stabilize microtubules and foster themaintenance of primary cilium. The VHL protein also promotes the stabilization and activation of p53 and, in neuronal cells, promotesapoptosis by downregulation of Jun-B [173]. It was furthermore shown that acute VHL inactivation causes a senescent-like phenotypeindependently of HIF but dependent on the retinoblastoma protein (Rb) and the SWI2/SNF2 chromatin remodeler p400 [174].

Biallelic inactivation of the VHL tumor suppressor gene is suspected as initiating step of tumorigenesis. In general, two genetic eventsor “hits” are thought to occur to the two alleles of a tumor suppressor gene: The first hit is represented by a germline mutation and thesecond hit is characterized by inactivation of the wild-type allele [175]. More recent work suggests, that the biallelic VHL inactivation isonly a first step in VHL tumorigenesis.

Tumorigenesis in VHL disease shares fundamental principles in the different affected organ systems: Germline VHL inactivation leadsto persistence of microscopic developmentally arrested structures. These microscopic cell clusters already reveal biallelic VHLinactivation and consequent up-regulation of hypoxia inducible factor and down-stream targets like VEGF, EPO etc. This principle hasbeen shown for CNS hemangioblastomas [61, 62], renal cell carcinomas [176], endolymphatic sac tumors [154] and epididymalcystadenomas [140] and is most likely valid for all VHL associated tumors.

Current research for pharmacotherapy of VHL disease targets proteins of the HIF cascade [33]. Additionally investigated arecompounds that lead to upregulation and re-functionalization of mutated VHL protein [177].

REFERENCESMaher E.R., Iselius L., Yates J.R., Littler M., Benjamin C., Harris R., Sampson J., Williams A., Ferguson-Smith M.A., Morton N.Von Hippel-Lindau disease: a genetic study. J Med Genet. 1991;28(7):443–7. [PMC free article: PMC1016952] [PubMed: 1895313]Neumann H.P., Wiestler O.D. Clustering of features and genetics of von Hippel-Lindau syndrome. Lancet. 1991;338(8761):258.


9 of 18 2/11/19, 8:44 AM

3.

4.5.

6.7.

8.

9.

10.11.

12.13.

14.

15.16.

17.18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.

[letter; comment] p. [PubMed: 1676812]Maher E.R., Yates J.R., Harries R., Benjamin C., Harris R., Moore A.T., Ferguson-Smith M.A. Clinical features and natural historyof von Hippel-Lindau disease. Q J Med. 1990;77(283):1151–63. [see comments] p. [PubMed: 2274658]von Hippel E. Ueber eine seltene Erkrankung der Netzhaut. Graefes Arch Opthalmol. 1904;59:83–106.Lindau A. Studien uber Kleinhirnzysten. Bau, Pathogenese und Beziehung zur Angiomatosis retinae. Acta Path et Microbiol Scand.1926 Suppl 1:1–126.Lindau A. Zur Frage der Angiomatosis retinae und ihrer Hirnkomplikation. Acta Ophthalmol (Copenh). 1927;4:193–226.Zbar B., Kishida T., Chen F., Schmidt L., Maher E.R., Richards F.M., Crossey P.A., Webster A.R., Affara N.A., Ferguson-SmithM.A., Brauch H., Glavac D., Neumann H.P., Tisherman S., Mulvihill J.J., Gross D.J., Shuin T., Whaley J., Seizinger B., Kley N.,Olschwang S., Boisson C., Richard S., Lips C.H., Lerman M., et al. Germline mutations in the Von Hippel-Lindau disease (VHL)gene in families from North America, Europe, and Japan. Hum Mutat. 1996;8(4):348–57. [PubMed: 8956040]DeLellis, R.A., P.U. Heitz, R.V. Lloyd, and C. Eng, eds. Pathology and molecular genetics of endocrine tumours. WHOclassification of tumours of endocrine organs. 2003, IARC press: Lyon.Lonser R.R., Glenn G.M., Walther M., Chew E.Y., Libutti S.K., Linehan W.M., Oldfield E.H. von Hippel-Lindau disease. Lancet.2003;361(9374):2059–67. [PubMed: 12814730]Maher E.R., Kaelin W.G. Jr. von Hippel-Lindau disease. Medicine (Baltimore). 1997;76(6):381–91. [PubMed: 9413424]Lamiell J.M., Salazar F.G., Hsia Y.E. von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore).1989;68(1):1–29. [PubMed: 2642584]Friedrich C.A. Von Hippel-Lindau syndrome. A pleomorphic condition. Cancer. 1999;86(11) Suppl:2478–82. [PubMed: 10630173]Wanebo J., Lonser R., Glenn G., Oldfield E. The natural history of hemangioblastomas of the central nervous system in patientswith von Hippel-Lindau disease. J Neurosurg. 2003;98(1):82–94. [PubMed: 12546356]Lonser R.R., Butman J.A., Huntoon K., Asthagiri A.R., Wu T., Bakhtian K.D., Chew E.Y., Zhuang Z., Linehan W.M., OldfieldE.H. Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease. J Neurosurg.2014;120(5):1055–62. [PMC free article: PMC4762041] [PubMed: 24579662]Neumann H.P. Prognosis of von Hippel-Lindau syndrome. Vasa. 1987;16(4):309–11. [PubMed: 3424948]Lonser R.R., Vortmeyer A.O., Butman J.A., Glasker S., Finn M.A., Ammerman J.M., Merrill M.J., Edwards N.A., Zhuang Z.,Oldfield E.H. Edema is a precursor to central nervous system peritumoral cyst formation. Ann Neurol. 2005;58(3):392–9.[PubMed: 16130092]Carpenter G., Schwartz H., Walker A. Neurogenic polycythemia. Ann Intern Med. 1943;19(3):470–81.Glasker S., Kruger M.T., Klingler J.H., Wlodarski M., Klompen J., Schatlo B., Hippchen B., Neumann H.P., Van Velthoven V.Hemangioblastomas and neurogenic polyglobulia. Neurosurgery. 2013;72(6):930–5. [PubMed: 23407287]Resche F., Moisan J.P., Mantoura J., de Kersaint-Gilly A., Andre M.J., Perrin-Resche I., Menegalli-Boggelli D., Lajat Y., RichardS. Haemangioblastoma, haemangioblastomatosis, and von Hippel-Lindau disease. Adv Tech Stand Neurosurg. 1993;20:197–304.[PubMed: 8397535]Filling-Katz M.R., Choyke P.L., Oldfield E., Charnas L., Patronas N.J., Glenn G.M., Gorin M.B., Morgan J.K., Linehan W.M.,Seizinger B.R., et al. Central nervous system involvement in Von Hippel-Lindau disease. Neurology. 1991;41(1):41–6. [PubMed:1985294]Weil R., Lonser R., DeVroom H., Wanebo J., Oldfield E. Surgical management of brainstem hemangioblastomas in patients withvon Hippel-Lindau disease. J Neurosurg. 2003;98(1):95–105. [PubMed: 12546357]van Velthoven V., Reinacher P.C., Klisch J., Neumann H.P., Glasker S. Treatment of intramedullary hemangioblastomas, withspecial attention to von Hippel-Lindau disease. Neurosurgery. 2003;53(6):1306–13. [PubMed: 14633297]Chang S.D., Meisel J.A., Hancock S.L., Martin D.P., McManus M., Adler J.R. Jr. Treatment of hemangioblastomas in von Hippel-Lindau disease with linear accelerator-based radiosurgery. Neurosurgery. 1998;43(1):28–34. [PubMed: 9657185]Patrice S.J., Sneed P.K., Flickinger J.C., Shrieve D.C., Pollock B.E., Alexander E. 3rd, Larson D.A., Kondziolka D.S., Gutin P.H.,Wara W.M., McDermott M.W., Lunsford L.D., Loeffler J.S. Radiosurgery for hemangioblastoma: results of a multiinstitutionalexperience. Int J Radiat Oncol Biol Phys. 1996;35(3):493–9. [PubMed: 8655372]Niemela M., Lim Y.J., Soderman M., Jaaskelainen J., Lindquist C. Gamma knife radiosurgery in 11 hemangioblastomas. JNeurosurg. 1996;85(4):591–6. [PubMed: 8814161]Pan L., Wang E.M., Wang B.J., Zhou L.F., Zhang N., Cai P.W., Da J.Z. Gamma knife radiosurgery for hemangioblastomas.Stereotact Funct Neurosurg. 1998;70 Suppl 1:179–86. [PubMed: 9782249]Jawahar A., Kondziolka D., Garces Y.I., Flickinger J.C., Pollock B.E., Lunsford L.D. Stereotactic radiosurgery forhemangioblastomas of the brain. Acta Neurochirurgica. 2000;142(6):641–4. [PubMed: 10949438]Madhusudan S., Deplanque G., Braybrooke J.P., Cattell E., Taylor M., Price P., Tsaloumas M.D., Moore N., Huson S.M., AdamsC., Frith P., Scigalla P., Harris A.L. Antiangiogenic therapy for von Hippel-Lindau disease. JAMA. 2004;291(8):943–4. [PubMed:14982909]Richard S., Croisille L., Yvart J., Casadeval N., Eschwege P., Aghakhani N., David P., Gaudric A., Scigalla P., Hermine O.


10 of 18 2/11/19, 8:44 AM

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

40.

41.

42.

43.

44.

45.

46.

47.

48.

49.

50.

Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptortherapy. Blood. 2002;99(10):3851–3. [PubMed: 11986247]

Aiello L.P., George D.J., Cahill M.T., Wong J.S., Cavallerano J., Hannah A.L., Kaelin W.G. Jr. Rapid and durable recovery ofvisual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factorreceptor inhibitor su5416. Ophthalmology. 2002;109(9):1745–51. [PubMed: 12208726]Girmens J.F., Erginay A., Massin P., Scigalla P., Gaudric A., Richard S. Treatment of von Hippel-Lindau retinal hemangioblastomaby the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than forhemangioblastomas. Am J Ophthalmol. 2003;136(1):194–6. [PubMed: 12834696]Schuch G., de Wit M., Holtje J., Laack E., Schilling G., Hossfeld D.K., Fiedler W., Scigalla P., Jacobs M.S. Case 2.Hemangioblastomas: diagnosis of von Hippel-Lindau disease and antiangiogenic treatment with SU5416. J Clin Oncol.2005;23(15):3624–6. [PubMed: 15908674]Jonasch E., McCutcheon I.E., Waguespack S.G., Wen S., Davis D.W., Smith L.A., Tannir N.M., Gombos D.S., Fuller G.N., MatinS.F. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol. 2011;22(12):2661–6. [PMC free article:PMC4542805] [PubMed: 22105611]Knickelbein J.E., Jacobs-El N., Wong W.T., Wiley H.E., Cukras C.A., Meyerle C.B., Chew E.Y. Systemic Sunitinib MalateTreatment for Advanced Juxtapapillary Retinal Hemangioblastomas Associated with von Hippel-Lindau Disease. OphthalmolRetina. 2017;1(3):181–187. [PMC free article: PMC5490440] [PubMed: 28670632]Reyes-Botero G., Gallego Perez-Larraya J., Sanson M. Sporadic CNS hemangioblastomatosis, response to sunitinib and secondarypolycythemia. J Neurooncol. 2012;107(2):439–40. [PubMed: 22076450]Roma A., Maruzzo M., Basso U., Brunello A., Zamarchi R., Bezzon E., Pomerri F., Zovato S., Opocher G., Zagonel V. First-Linesunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns ofradiological response. Fam Cancer. 2015;14(2):309–16. [PubMed: 25391617]Pilie P., Hasanov E., Matin S.F., Woodson A.H.H., Marcott V.D., Bird S., Slack R.S., Fuller G.N., McCutcheon I.E., Jonasch E.Pilot study of dovitinib in patients with von Hippel-Lindau disease. Oncotarget. 2018;9(34):23390–23395. [PMC free article:PMC5955100] [PubMed: 29805741]Kim B.Y., Jonasch E., McCutcheon I.E. Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease: casereport. Target Oncol. 2012;7(2):145–9. [PMC free article: PMC5033110] [PubMed: 22374327]Migliorini D., Haller S., Merkler D., Pugliesi-Rinaldi A., Koka A., Schaller K., Leemann B., Dietrich P.Y. Recurrent multiple CNShemangioblastomas with VHL disease treated with pazopanib: a case report and literature review. CNS Oncol. 2015;4(6):387–92.[PMC free article: PMC6083944] [PubMed: 26497655]Taylor D.G., Ilyas A., Mehta G.U., Chen C.J., Schiff D., Oldfield E.H., Asthagiri A.R. Variable response of CNShemangioblastomas to Pazopanib in a single patient with von Hippel-Lindau disease: Case report. J Clin Neurosci.2018;50:154–156. [PubMed: 29396065]Glasker S., Van Velthoven V. Risk of hemorrhage in hemangioblastomas of the central nervous system. Neurosurgery.2005;57(1):71–6. [PubMed: 15987542]Seong Eom K., Won Kim D., Sung Choi S., Ha Choi K., Young Kim T. Preoperative embolization of a cerebellarhaemangioblastoma using Onyx: case report and literature review. Neurol Neurochir Pol. 2011;45(3):292–6. [PubMed: 21866486]Glasker S., Klingler J.H., Wurtenberger C., Muller K., Hader C., Zentner J., Neumann H.P., Van Velthoven V. Essentials andpitfalls in treatment of hemangioblastoma and von Hippel-Lindau disease. Central European Neurosurgery. 2010;71(2):80–7.[PubMed: 20229452]Glasker S., Shah M.J., Hippchen B., Neumann H.P., Van Velthoven V. Doppler-Sonographically Guided Resection of CNSHemangioblastomas. Neurosurgery. 2011;68:ons267–ons275. [PubMed: 21346656]Takeshima Y., Tanaka Y., Hironaka Y., Shida Y., Nakase H. Visualization of vascular structure of spinal hemangioblastoma usingintraoperative indocyanine green videoangiography and temporary feeder occlusion. Eur Spine J. 2015 [PubMed: 25563200]Benedetto N., Aquila F., Vannozzi R. Use of near-infrared indocyanine videoangiography and Flow 800 in the resectioning of aspinal cord haemangioblastoma. Br J Neurosurg. 2013;27(6):847–9. [PubMed: 23705578]Hojo M., Arakawa Y., Funaki T., Yoshida K., Kikuchi T., Takagi Y., Araki Y., Ishii A., Kunieda T., Takahashi J.C., Miyamoto S.Usefulness of tumor blood flow imaging by intraoperative indocyanine green videoangiography in hemangioblastoma surgery.World Neurosurg. 2014;82(3-4):e495–501. [PubMed: 23396070]Tamura Y., Hirota Y., Miyata S., Yamada Y., Tucker A., Kuroiwa T. The use of intraoperative near-infrared indocyanine greenvideoangiography in the microscopic resection of hemangioblastomas. Acta Neurochir (Wien). 2012;154(8):1407–12. [PubMed:22718141]Hwang, S.W., A.M. Malek, R. Schapiro, and J.K. Wu, Intraoperative use of indocyanine green fluorescence videography forresection of a spinal cord hemangioblastoma. Neurosurgery, 2010. 67(3 Suppl Operative): p. ons300-3; discussion ons303.[PubMed: 20679920]Hao S., Li D., Ma G., Yang J., Wang G. Application of intraoperative indocyanine green videoangiography for resection of spinal


11 of 18 2/11/19, 8:44 AM

51.

52.

53.

54.

55.

56.

57.

58.

59.

60.

61.

62.

63.

64.

65.

66.

67.

68.

69.

70.

71.

72.

73.

cord hemangioblastoma: advantages and limitations. J Clin Neurosci. 2013;20(9):1269–75. [PubMed: 23845264]Vortmeyer A.O., Gnarra J.R., Emmert-Buck M.R., Katz D., Linehan W.M., Oldfield E.H., Zhuang Z. von Hippel-Lindau genedeletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. HumPathol. 1997;28(5):540–3. [PubMed: 9158701]Becker I., Paulus W., Roggendorf W. Histogenesis of stromal cells in cerebellar hemangioblastomas. Am J Pathol.1989;134:271–5. [PMC free article: PMC1879587] [PubMed: 2916647]Lach B., Gregor A., Rippstein P., Omulecka A. Angiogenic histogenesis of stromal cells in hemangioblastoma: ultrastructural andimmunohistochemical study. Ultrastruct Pathol. 1999;23(5):299–310. [PubMed: 10582267]Omulecka A., Lach B., Alwasiak J., Gregor A. Immunohistochemical and ultrastructural studies of stromal cells inhemangioblastoma. Folia Neuropathol. 1995;33(1):41–50. [PubMed: 8673419]Ishizawa K., Komori T., Hirose T. Stromal cells in hemangioblastoma: Neuroectodermal differentiation and morphologicalsimilarities to ependymoma. Pathol Int. 2005;55(7):377–85. [PubMed: 15982211]Bohling, T., K.H. Plate, M. Haltia, K. Alitalo, and H.P.H. Neumann, Von Hippel-Lindau disease and capillary hemangioblastoma,in Pathology and genetics of tumours of the central nervous system, P. Kleihues and W.K. Cawenee, Editors. 2000, World HealthOrganization: Lyon. p. 223-226.Cruz-Sanchez F.F., Rossi M.L., Rodriguez-Prados S., Nakamura N., Hughes J.T., Coakham H.B. Haemangioblastoma: histologicaland immunohistological study of an enigmatic cerebellar tumour. Histol Histopathol. 1990;5(4):407–13. [PubMed: 2134394]Ding X.H., Zhou L.F., Tan Y.Z., Zhao Y., Zhu J.J. Histologic and histogenetic investigations of intracranial hemangioblastomas.Surg Neurol. 2007;67(3):239–45. [PubMed: 17320626]Shively S.B., Falke E.A., Li J., Tran M.G., Thompson E.R., Maxwell P.H., Roessler E., Oldfield E.H., Lonser R.R., VortmeyerA.O. Developmentally arrested structures preceding cerebellar tumors in von Hippel-Lindau disease. Mod Pathol.2011;24(8):1023–30. [PMC free article: PMC3182838] [PubMed: 21499240]Vortmeyer A.O., Tran M., Zeng W., Glasker S., Riley C., Tsokos M., Ikejiri B., Merrill M.J., Raffeld M., Zhuang Z., Lonser R.R.,Maxwell P.H., Oldfield E.H. Evolution of VHL tumorigenesis in nerve root tissue. J Pathol. 2006;210(3):374–82. [PubMed:16981244]Vortmeyer A.O., Yuan Q., Lee Y.S., Zhuang Z., Oldfield E.H. Developmental effects of von Hippel-Lindau gene deficiency. Annalsof Neurology. 2004;55(5):721–8. [PubMed: 15122713]Vortmeyer A.O., Frank S., Jeong S.Y., Yuan K., Ikejiri B., Lee Y.S., Bhowmick D., Lonser R.R., Smith R., Rodgers G., OldfieldE.H., Zhuang Z. Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. CancerResearch. 2003;63(21):7051–5. [PubMed: 14612494]Glasker S., Li J., Xia J.B., Okamoto H., Zeng W., Lonser R.R., Zhuang Z., Oldfield E.H., Vortmeyer A.O. Hemangioblastomasshare protein expression with embryonal hemangioblast progenitor cell. Cancer Research. 2006;66(8):4167–4172. [PubMed:16618738]Barresi V., Vitarelli E., Branca G., Antonelli M., Giangaspero F., Barresi G. Expression of Brachyury in Hemangioblastoma:Potential Use in Differential Diagnosis. Am J Surg Pathol. 2012 [PubMed: 22446946]Park D.M., Zhuang Z., Chen L., Szerlip N., Maric I., Li J., Sohn T., Kim S.H., Lubensky I.A., Vortmeyer A.O., Rodgers G.P.,Oldfield E.H., Lonser R.R. von Hippel-Lindau Disease-Associated Hemangioblastomas Are Derived from EmbryologicMultipotent Cells. PLoS Med. 2007;4(2):e60. [PMC free article: PMC1796910] [PubMed: 17298169]Barresi V., Ieni A., Branca G., Tuccari G. Brachyury: a diagnostic marker for the differential diagnosis of chordoma andhemangioblastoma versus neoplastic histological mimickers. Dis Markers. 2014;2014:514753. [PMC free article: PMC3925620][PubMed: 24591762]Zec N., Cera P., Towfighi J. Extramedullary hematopoiesis in cerebellar hemangioblastoma. Neurosurgery. 1991;29(1):34–7.[PubMed: 1870685]Stein A.A., Schilp A.O., Whitfield R.D. The histogenesis of hemangioblastoma of the brain. A review of twenty-one cases. JNeurosurg. 1960;17:751–61. [PubMed: 13834086]Vortmeyer A.O., Frank S., Jeong S.Y., Yuan K., Ikejiri B., Lee Y.S., Bhowmick D., Lonser R.R., Smith R., Rodgers G., OldfieldE.H., Zhuang Z. Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Res.2003;63(21):7051–5. [PubMed: 14612494]Vortmeyer A.O., Yuan Q., Lee Y.S., Zhuang Z., Oldfield E.H. Developmental effects of von Hippel-Lindau gene deficiency. AnnNeurol. 2004;55(5):721–8. [PubMed: 15122713]Vortmeyer A.O., Tran M.G., Zeng W., Glasker S., Riley C., Tsokos M., Ikejiri B., Merrill M.J., Raffeld M., Zhuang Z., LonserR.R., Maxwell P.H., Oldfield E.H. Evolution of VHL tumourigenesis in nerve root tissue. J Pathol. 2006;210(3):374–82. [PubMed:16981244]Glasker S., Smith J., Raffeld M., Li J., Oldfield E.H., Vortmeyer A.O. VHL-deficient vasculogenesis in hemangioblastoma. ExpMol Pathol. 2014;96(2):162–7. [PubMed: 24394472]Zhuang Z., Frerich J.M., Huntoon K., Yang C., Merrill M.J., Abdullaev Z., Pack S.D., Shively S.B., Stamp G., Lonser R.R. Tumor


12 of 18 2/11/19, 8:44 AM

74.

75.

76.

77.

78.

79.

80.

81.

82.

83.

84.

85.

86.

87.

88.

89.

90.

91.

92.

93.

94.

95.

derived vasculogenesis in von Hippel-Lindau disease-associated tumors. Sci Rep. 2014;4:4102. [PMC free article: PMC3925948][PubMed: 24531117]

Chan C.C., Vortmeyer A.O., Chew E.Y., Green W.R., Matteson D.M., Shen D.F., Linehan W.M., Lubensky I.A., Zhuang Z. VHLgene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma. Arch Ophthalmol.1999;117(5):625–30. [PubMed: 10326959]Singh A.D., Nouri M., Shields C.L., Shields J.A., Perez N. Treatment of retinal capillary hemangioma. Ophthalmology.2002;109(10):1799–806. [PubMed: 12359597]Schmidt D., Natt E., Neumann H.P. Long-term results of laser treatment for retinal angiomatosis in von Hippel-Lindau disease. EurJ Med Res. 2000;5(2):47–58. [PubMed: 10720563]Gaudric A., Krivosic V., Duguid G., Massin P., Giraud S., Richard S. Vitreoretinal surgery for severe retinal capillary hemangiomasin von hippel-lindau disease. Ophthalmology. 2011;118(1):142–9. [PubMed: 20801520]Ach T., Thiemeyer D., Hoeh A.E., Schaal K.B., Dithmar S. Intravitreal bevacizumab for retinal capillary haemangioma: longtermresults. Acta Ophthalmol. 2010;88(4):e137–8. [PubMed: 19681788]Slim E., Antoun J., Kourie H.R., Schakkal A., Cherfan G. A case series and literature review. Can J Ophthalmol.2014;49(5):450–7. [PubMed: 25284102]Matsuo T., Himei K., Ichimura K., Yanai H., Nose S., Mimura T., Miyoshi Y., Tsushima T. Long-term effect of external beamradiotherapy of optic disc hemangioma in a patient with von Hippel-Lindau disease. Acta Med Okayama. 2011;65(2):135–41.[PubMed: 21519372]Ueba T., Abe H., Matsumoto J., Higashi T., Inoue T. Efficacy of indocyanine green videography and real-time evaluation byFLOW 800 in the resection of a spinal cord hemangioblastoma in a child: case report. J Neurosurg Pediatr. 2012;9(4):428–31.[PubMed: 22462710]Chew E.Y. Ocular manifestations of von Hippel-Lindau disease: clinical and genetic investigations. Trans Am Ophthalmol Soc.2005;103:495–511. [PMC free article: PMC1447586] [PubMed: 17057815]Bahougne T., Romanet P., Mohamed A., Caselles K., Cuny T., Barlier A., Niccoli P. Functioning Mediastinal ParagangliomaAssociated with a Germline Mutation of von Hippel-Lindau Gene. J Clin Med. 2018;7(6) [PMC free article: PMC6025296][PubMed: 29789510]Lubensky I.A., Gnarra J.R., Bertheau P., Walther M.M., Linehan W.M., Zhuang Z. Allelic deletions of the VHL gene detected inmultiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol. 1996;149(6):2089–94. [PMC freearticle: PMC1865348] [PubMed: 8952541]Neumann H.P., Riegler P., Huber W., Corradini R., Sessa A., Fontana D., Wetterauer U., Janetschek G. The challenge of kidneylesions in von Hippel-Lindau disease. Contributions to Nephrology. 2001;136:193–207. [Review] [39 refs] p. [PubMed: 11688380]Richard S., D., Chauveau Y., Chretien C., Beigelman A., Denys J.P., Fendler G., Fromont F., Paraf O., Helenon S. Renal lesionsand pheochromocytoma in von Hippel-Lindau disease. Adv Nephrol Necker Hosp. 1994;23:1–27. Nizard, and et al. p. [PubMed:8154348]Grubb R.L. 3rd, Choyke P.L., Pinto P.A., Linehan W.M., Walther M.M. Management of von Hippel-Lindau-associated kidneycancer. Nat Clin Pract Urol. 2005;2(5):248–55. [PubMed: 16474836]Kaelin W.G. Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res. 2004;10(18 Pt 2):6290S–5S.[PubMed: 15448019]Linehan W.M., Walther M.M., Zbar B. The genetic basis of cancer of the kidney. Journal of Urology. 2003;170(6 Pt 1):2163–72.[PubMed: 14634372]Choyke P.L., Glenn G.M., Walther M.M., Zbar B., Weiss G.H., Alexander R.B., Hayes W.S., Long J.P., Thakore K.N., LinehanW.M. The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. American Journal ofRoentgenology. 1992;159:1229–34. [PubMed: 1442389]Poston C.D., Jaffe G.S., Lubensky I.A., Solomon D., Zbar B., Linehan W.M., Walther M.M. Characterization of the renalpathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular geneticimplications. Journal of Urology. 1995;153(1):22–6. [PubMed: 7966777]Walther M.M., Choyke P.L., Glenn G., Lyne J.C., Rayford W., Venzon D., Linehan W.M. Renal cancer in families with hereditaryrenal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol. 1999;161(5):1475–9.[PubMed: 10210376]Jilg C.A., Neumann H.P., Glasker S., Schafer O., Ardelt P.U., Schwardt M., Schultze-Seemann W. Growth Kinetics in Von Hippel-Lindau-Associated Renal Cell Carcinoma. Urol Int. 2012;88(1):71–8. [PubMed: 22156657]Walther M.M., Choyke P.L., Weiss G., Manolatos C., Long J., Reiter R., Alexander R.B., Linehan W.M. Parenchymal sparingsurgery in patients with hereditary renal cell carcinoma. J Urol. 1995;153(3 Pt 2):913–6. [PubMed: 7853573]Jilg C.A., Neumann H.P., Glasker S., Schafer O., Leiber C., Ardelt P.U., Schwardt M., Schultze-Seemann W. Nephron sparingsurgery in von Hippel-Lindau associated renal cell carcinoma; clinicopathological long-term follow-up. Fam Cancer. 2012[PubMed: 22426863]


13 of 18 2/11/19, 8:44 AM

96.

97.98.

99.

100.

101.

102.

103.

104.

105.

106.

107.

108.

109.

110.

111.

112.

113.

114.

115.

Allasia M., Soria F., Battaglia A., Gazzera C., Calandri M., Caprino M.P., Lucatello B., Velrti A., Maccario M., Pasini B., Bosio A.,Gontero P., Destefanis P. Radiofrequency Ablation for Renal Cancer in Von Hippel-Lindau Syndrome Patients: A ProspectiveCohort Analysis. Clin Genitourin Cancer. 2017 [PubMed: 28866246]Welsh S.J., Fife K. Pazopanib for the treatment of renal cell carcinoma. Future Oncol. 2015;11(8):1169–79. [PubMed: 25832874]Jafri M., Maher E.R. The genetics of phaeochromocytoma: using clinical features to guide genetic testing. Eur J Endocrinol.2012;166(2):151–8. [PubMed: 21896620]Neumann H.P., Bausch B., McWhinney S.R., Bender B.U., Gimm O., Franke G., Schipper J., Klisch J., Altehoefer C., Zerres K.,Januszewicz A., Eng C., Smith W.M., Munk R., Manz T., Glaesker S., Apel T.W., Treier M., Reineke M., Walz M.K., Hoang-VuC., Brauckhoff M., Klein-Franke A., Klose P., Schmidt H., Maier-Woelfle M., Peczkowska M., Szmigielski C. Germ-linemutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346(19):1459–66. [PubMed: 12000816]Koch C.A., Mauro D., Walther M.M., Linehan W.M., Vortmeyer A.O., Jaffe R., Pacak K., Chrousos G.P., Zhuang Z., LubenskyI.A. Pheochromocytoma in von hippel-lindau disease: distinct histopathologic phenotype compared to pheochromocytoma inmultiple endocrine neoplasia type 2. Endocr Pathol. 2002;13(1):17–27. [PubMed: 12114747]Walther M.M., Reiter R., Keiser H.R., Choyke P.L., Venzon D., Hurley K., Gnarra J.R., Reynolds J.C., Glenn G.M., Zbar B.,Linehan W.M. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison withsporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol. 1999;162(3 Pt 1):659–64. [PubMed:10458336]Weisbrod A.B., Kitano M., Gesuwan K., Millo C., Herscovitch P., Nilubol N., Linehan W.M., Kebebew E. Clinical utility offunctional imaging with 18F-FDOPA in Von Hippel-Lindau syndrome. J Clin Endocrinol Metab. 2012;97(4):E613–7. [PMC freearticle: PMC3319180] [PubMed: 22259055]Kudva Y.C., Young W.F., Thompson G.B. Endocrinologist. 1999;9:77–81. and e. al., Adrenal incidentaloma: an importantcomponent of the clinical presentation spectrum of benign sporadic adrenal pheochromocytoma. p.Motta-Ramirez G.A., Remer E.M., Herts B.R., Gill I.S., Hamrahian A.H. Comparison of CT findings in symptomatic andincidentally discovered pheochromocytomas. AJR Am J Roentgenol. 2005;185(3):684–8. [PubMed: 16120918]Welander J., Soderkvist P., Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas.Endocr Relat Cancer. 2011;18(6):R253–76. [PubMed: 22041710]Papaspyrou K., Mewes T., Rossmann H., Fottner C., Schneider-Raetzke B., Bartsch O., Schreckenberger M., Lackner K.J.,Amedee R.G., Mann W.J. Head and neck paragangliomas: Report of 175 patients (1989-2010). Head Neck. 2012;34(5):632–7.[PubMed: 21692132]Gaal J., van Nederveen F.H., Erlic Z., Korpershoek E., Oldenburg R., Boedeker C.C., Kontny U., Neumann H.P., Dinjens W.N.,de Krijger R.R. Parasympathetic paragangliomas are part of the Von Hippel-Lindau syndrome. J Clin Endocrinol Metab.2009;94(11):4367–71. [PubMed: 19808854]Boedeker C.C., Erlic Z., Richard S., Kontny U., Gimenez-Roqueplo A.P., Cascon A., Robledo M., de Campos J.M., vanNederveen F.H., de Krijger R.R., Burnichon N., Gaal J., Walter M.A., Reschke K., Wiech T., Weber J., Ruckauer K., Plouin P.F.,Darrouzet V., Giraud S., Eng C., Neumann H.P. Head and neck paragangliomas in von Hippel-Lindau disease and multipleendocrine neoplasia type 2. J Clin Endocrinol Metab. 2009;94(6):1938–44. [PMC free article: PMC2690424] [PubMed:19336503]Liu Q., Yuan G., Tong D., Liu G., Yi Y., Zhang J., Zhang Y., Wang L.A., Wang L., Zhang D., Chen R., Guan Y., Yi X., Lan W.,Jiang J. Novel genotype-phenotype correlations in five Chinese families with Von Hippel-Lindau disease. Endocr Connect.2018;7(7):870–878. [PMC free article: PMC6026882] [PubMed: 29871882]Lomte N., Kumar S., Sarathi V., Pandit R., Goroshi M., Jadhav S., Lila A.R., Bandgar T., Shah N.S. Genotype phenotypecorrelation in Asian Indian von Hippel-Lindau (VHL) syndrome patients with pheochromocytoma/paraganglioma. Fam Cancer.2018;17(3):441–449. [PubMed: 29124493]Pandit R., Khadilkar K., Sarathi V., Kasaliwal R., Goroshi M., Khare S., Nair S., Raghavan V., Dalvi A., Hira P., Fernandes G.,Sathe P., Rojekar A., Malhotra G., Bakshi G., Prakash G., Bhansali A., Walia R., Kamalanathan S., Sahoo J., Desai A., BhagwatN., Mappa P., Rajput R., Chandrashekhar S.R., Shivane V., Menon P., Lila A., Bandgar T., Shah N. Germline mutations andgenotype-phenotype correlation in Asian Indian patients with pheochromocytoma and paraganglioma. Eur J Endocrinol.2016;175(4):311–23. [PubMed: 27539324]Astapova O., Biswas A., DiMauro A., Moalem J., Hammes S.R. Bilateral Pheochromocytomas in a Patient with Y175C VonHippel-Lindau Mutation. Case Rep Endocrinol. 2018;2018:8967159. [PMC free article: PMC6076969] [PubMed: 30105105]Bhatia K.S., Ismail M.M., Sahdev A., Rockall A.G., Hogarth K., Canizales A., Avril N., Monson J.P., Grossman A.B., ReznekR.H. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas:CT and MRI correlation. Clin Endocrinol (Oxf). 2008;69(2):181–8. [PubMed: 18394016]Koch C.A., Vortmeyer A.O., Diallo R., Poremba C., Giordano T.J., Sanders D., Bornstein S.R., Chrousos G.P., Pacak K. Survivin:a novel neuroendocrine marker for pheochromocytoma. Eur J Endocrinol. 2002;146(3):381–8. [PubMed: 11888845]Pacak, K., G.P. Chrousos, C.A. Koch, and G. Eisenhofer, Pheochromocytoma: progress in diagnosis, therapy, and genetics., in


14 of 18 2/11/19, 8:44 AM

116.

117.

118.

119.

120.

121.

122.

123.

124.

125.

126.

127.

128.

129.

130.

131.

132.

133.

134.

135.

Adrenal Disorders, A. Margioris and G.P. Chrousos, Editors. 2001, Humana Press: New York. p. 379-413.Colvin A., Saltzman A.F., Walker J., Bruny J., Cost N.G. Metastatic Pheochromocytoma in an Asymptomatic 12-Year-Old Withvon Hippel-Lindau Disease. Urology. 2018 [PubMed: 29545044]Kimura, N., R. Chetty, C. Capella, W.F. Young, C.A. Koch, K.Y. Lam, R.A. DeLellis, A. Kawashima, P. Komminoth, and A.Tischler, Tumours of the Adrenal Medulla and Extraadrenal Paraganglia, in WHO Classification of Tumours of EndocrineOrgans, R.V. Lloyd, et al., Editors. 2017, WHO Blue Book Series 2017.Kaluarachchi V.T.S., Bulugahapitiya U., Arambewela M., Gunathilake S. Successful Management of PheochromocytomaDetected in Pregnancy by Interval Adrenalectomy in a VHL Patient. Case Rep Endocrinol. 2018;2018:9014585. [PMC freearticle: PMC6076903] [PubMed: 30105106]Eisenhofer G., Lenders J.W., Timmers H., Mannelli M., Grebe S.K., Hofbauer L.C., Bornstein S.R., Tiebel O., Adams K.,Bratslavsky G., Linehan W.M., Pacak K. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine asdiscriminators of different hereditary forms of pheochromocytoma. Clin Chem. 2011;57(3):411–20. [PMC free article:PMC3164998] [PubMed: 21262951]Eisenhofer G., Lenders J.W., Linehan W.M., Walther M.M., Goldstein D.S., Keiser H.R. Plasma normetanephrine andmetanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl JMed. 1999;340(24):1872–9. [PubMed: 10369850]Nielsen S.M., Rubinstein W.S., Thull D.L., Armstrong M.J., Feingold E., Stang M.T., Gnarra J.R., Carty S.E. Genotype-phenotype correlations of pheochromocytoma in two large von Hippel-Lindau (VHL) type 2A kindreds with different missensemutations. Am J Med Genet A. 2011;155A(1):168–73. [PMC free article: PMC3085839] [PubMed: 21204227]Launbjerg K., Bache I., Galanakis M., Bisgaard M.L., Binderup M.L.M. von Hippel-Lindau development in children andadolescents. Am J Med Genet A. 2017;173(9):2381–2394. [PubMed: 28650583]Weise M., Merke D.P., Pacak K., Walther M.M., Eisenhofer G. Utility of plasma free metanephrines for detecting childhoodpheochromocytoma. J Clin Endocrinol Metab. 2002;87(5):1955–60. [PubMed: 11994324]Koch C.A. Should 123I-MIBG scintigraphy be part of the workup for pheochromocytomas? Nat Clin Pract Endocrinol Metab.2009;5(2):76–7. [PubMed: 19165218]Ritter M.M., Frilling A., Crossey P.A., Hoppner W., Maher E.R., Mulligan L., Ponder B.A., Engelhardt D. Isolated familialpheochromocytoma as a variant of von Hippel-Lindau disease. J Clin Endocrinol Metab. 1996;81(3):1035–7. [PubMed: 8772572]Gergics P., Patocs A., Toth M., Igaz P., Szucs N., Liko I., Fazakas F., Szabo I., Kovacs B., Glaz E., Racz K. Germline VHL genemutations in Hungarian families with von Hippel-Lindau disease and patients with apparently sporadic unilateralpheochromocytomas. Eur J Endocrinol. 2009;161(3):495–502. [PubMed: 19574279]Iacobone M., Schiavi F., Bottussi M., Taschin E., Bobisse S., Fassina A., Opocher G., Favia G. Is genetic screening indicated inapparently sporadic pheochromocytomas and paragangliomas? Surgery. 2011;150(6):1194–201. [PubMed: 22136840]Wu P., Zhang N., Wang X., Ning X., Li T., Bu D., Gong K. Family history of von Hippel-Lindau disease was uncommon inChinese patients: suggesting the higher frequency of de novo mutations in VHL gene in these patients. J Hum Genet.2012;57(4):238–43. [PubMed: 22357542]Eisenhofer G., Vocke C.D., Elkahloun A., Huynh T.T., Prodanov T., Lenders J.W., Timmers H.J., Benhammou J.N., LinehanW.M., Pacak K. Genetic Screening for von Hippel-Lindau Gene Mutations in Non-syndromic Pheochromocytoma: LowPrevalence and False-positives or Misdiagnosis Indicate a Need for Caution. Horm Metab Res. 2012;44(5):343–8. [PMC freearticle: PMC3501345] [PubMed: 22438210]Brunt L.M., Lairmore T.C., Doherty G.M., Quasebarth M.A., DeBenedetti M., Moley J.F. Adrenalectomy for familialpheochromocytoma in the laparoscopic era. Ann Surg. 2002;235(5):713–20. [PMC free article: PMC1422498] [PubMed:11981218]Neumann H.P., Reincke M., Bender B.U., Elsner R., Janetschek G. Preserved adrenocortical function after laparoscopic bilateraladrenal sparing surgery for hereditary pheochromocytoma. J Clin Endocrinol Metab. 1999;84(8):2608–10. [PubMed: 10443647]Walz M.K., Peitgen K., Neumann H.P., Janssen O.E., Philipp T., Mann K. Endoscopic treatment of solitary, bilateral, multiple,and recurrent pheochromocytomas and paragangliomas. World J Surg. 2002;26(8):1005–12. [PubMed: 12045858]Dickson P.V., Jimenez C., Chisholm G.B., Kennamer D.L., Ng C., Grubbs E.G., Evans D.B., Lee J.E., Perrier N.D. Posteriorretroperitoneoscopic adrenalectomy: a contemporary American experience. J Am Coll Surg. 2011;212(4):659–65. [PubMed:21463807]Castinetti F., Taieb D., Henry J.F., Walz M., Guerin C., Brue T., Conte-Devolx B., Neumann H.P., Sebag F. MANAGEMENT OFENDOCRINE DISEASE: Outcome of adrenal sparing surgery in heritable pheochromocytoma. Eur J Endocrinol.2016;174(1):R9–18. [PubMed: 26297495]Butz J.J., Yan Q., McKenzie T.J., Weingarten T.N., Cavalcante A.N., Bancos I., Young W.F. Jr, Schroeder D.R., Martin D.P.,Sprung J. Perioperative outcomes of syndromic paraganglioma and pheochromocytoma resection in patients with von Hippel-Lindau disease, multiple endocrine neoplasia type 2, or neurofibromatosis type 1. Surgery. 2017;162(6):1259–1269. [PubMed:28919049]


15 of 18 2/11/19, 8:44 AM

136.

137.

138.

139.

140.

141.

142.

143.

144.

145.

146.

147.

148.

149.

150.

151.

152.

153.

Yuan G., Liu Q., Tong D., Liu G., Yi Y., Zhang J., Zhang Y., Wang L.A., Wang L., Chen R., Guan Y., Yi X., Lan W., Jiang J. Aretrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease. Cancer Biol Ther. 2018:1–20.[PMC free article: PMC6154838] [PubMed: 29947576]Singer J., Koch C.A., Kassahun W., Lamesch P., Eisenhofer G., Kluge R., Lincke T., Seiwerts M., Borte G., Schierle K., PaschkeR. A patient with a large recurrent pheochromocytoma demonstrating the pitfalls of diagnosis. Nat Rev Endocrinol.2011;7(12):749–55. [PubMed: 21894215]Ayala-Ramirez M., Feng L., Johnson M.M., Ejaz S., Habra M.A., Rich T., Busaidy N., Cote G.J., Perrier N., Phan A., Patel S.,Waguespack S., Jimenez C. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas andsympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab.2011;96(3):717–25. [PubMed: 21190975]Choyke P.L., Glenn G.M., Wagner J.P., Lubensky I.A., Thakore K., Zbar B., Linehan W.M., Walther M.M. Epididymalcystadenomas in von Hippel-Lindau disease. Urology. 1997;49(6):926–31. [PubMed: 9187702]Glasker S., Tran M.G., Shively S.B., Ikejiri B., Lonser R.R., Maxwell P.H., Zhuang Z., Oldfield E.H., Vortmeyer A.O.Epididymal cystadenomas and epithelial tumorlets: Effects of VHL deficiency on human epididymis. J Pathol.2006;210(1):32–41. [PubMed: 16841375]Mehta G.U., Shively S.B., Duong H., Tran M.G., Moncrief T.J., Smith J.H., Li J., Edwards N.A., Lonser R.R., Zhuang Z., MerrillM.J., Raffeld M., Maxwell P.H., Oldfield E.H., Vortmeyer A.O. Progression of epididymal maldevelopment into hamartoma-likeneoplasia in VHL disease. Neoplasia. 2008;10(10):1146–53. [PMC free article: PMC2546591] [PubMed: 18813354]Lubensky I.A., Pack S., Ault D., Vortmeyer A.O., Libutti S.K., Choyke P.L., Walther M.M., Linehan W.M., Zhuang Z. Multipleneuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis.Am J Pathol. 1998;153(1):223–31. [PMC free article: PMC1852951] [PubMed: 9665483]Neumann H.P., E., Dinkel H., Brambs B., Wimmer H., Friedburg B., Volk G., Sigmund P., Riegler K., Haag P. Pancreatic lesionsin the von Hippel-Lindau syndrome. Gastroenterology. 1991;101(2):465–71. Schollmeyer, and et al. p. [PubMed: 2065922]Hough D.M., Stephens D.H., Johnson C.D., Binkovitz L.A. Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinicalsignificance, and CT findings. AJR Am J Roentgenol. 1994;162(5):1091–4. [PubMed: 8165988]Weisbrod A.B., Kitano M., Thomas F., Williams D., Gulati N., Gesuwan K., Liu Y., Venzon D., Turkbey I., Choyke P., Yao J.,Libutti S.K., Nilubol N., Linehan W.M., Kebebew E. Assessment of tumor growth in pancreatic neuroendocrine tumors in vonHippel Lindau syndrome. J Am Coll Surg. 2014;218(2):163–9. [PMC free article: PMC3896892] [PubMed: 24440063]Sharma A., Mukewar S., Vege S.S. Clinical Profile of Pancreatic Cystic Lesions in von Hippel-Lindau Disease: A Series of 48Patients Seen at a Tertiary Institution. Pancreas. 2017;46(7):948–952. [PubMed: 28697137]Prasad V., Tiling N., Denecke T., Brenner W., Plockinger U. Potential role of (68)Ga-DOTATOC PET/CT in screening forpancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease. Eur J Nucl Med Mol Imaging.2016;43(11):2014–20. [PubMed: 27293206]Krauss T., Ferrara A.M., Links T.P., Wellner U., Bancos I., Kvachenyuk A., Villar Gomez de Las Heras K., Yukina M.Y., PetrovR., Bullivant G., von Duecker L., Jadhav S., Ploeckinger U., Welin S., Schalin-Jantti C., Gimm O., Pfeifer M., Ngeow J., Hasse-Lazar K., Sanso G., Qi X., Ugurlu M.U., Diaz R.E., Wohllk N., Peczkowska M., Aberle J., Lourenco D.M. Jr, Pereira M.A.A.,Fragoso M., Hoff A.O., Almeida M.Q., Violante A.H.D., Quidute A.R.P., Zhang Z., Recasens M., Diaz L.R., Kunavisarut T.,Wannachalee T., Sirinvaravong S., Jonasch E., Grozinsky-Glasberg S., Fraenkel M., Beltsevich D., Egorov V.I., Bausch D., SchottM., Tiling N., Pennelli G., Zschiedrich S., Darr R., Ruf J., Denecke T., Link K.H., Zovato S., von Dobschuetz E., Yaremchuk S.,Amthauer H., Makay O., Patocs A., Walz M.K., Huber T.B., Seufert J., Hellman P., Kim R.H., Kuchinskaya E., Schiavi F.,Malinoc A., Reisch N., Jarzab B., Barontini M., Januszewicz A., Shah N., Young W.F. Jr, Opocher G., Eng C., Neumann H.P.H.,Bausch B. Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocr Relat Cancer.2018;25(9):783–793. [PubMed: 29748190]de Mestier L., Gaujoux S., Cros J., Hentic O., Vullierme M.P., Couvelard A., Cadiot G., Sauvanet A., Ruszniewski P., Richard S.,Hammel P. Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable andNot Influenced by Small Tumors Left in Place. Ann Surg. 2015 Aug;262(2):384–8. [PubMed: 25185468]Libutti S.K., Choyke P.L., Bartlett D.L., Vargas H., Walther M., Lubensky I., Glenn G., Linehan W.M., Alexander H.R. Pancreaticneuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery.1998;124(6):1153–9. [PubMed: 9854597]Libutti S.K., Choyke P.L., Alexander H.R., Glenn G., Bartlett D.L., Zbar B., Lubensky I., McKee S.A., Maher E.R., LinehanW.M., Walther M.M. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery. 2000;128(6):1022–7. [PubMed: 11114638]von Ducker L., Walz M.K., Voss C., Arnold G., Eng C., Neumann H.P. Laparoscopic organ-sparing resection of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. World J Surg. 2011;35(3):563–7. [PubMed: 21181474]O'Toole S.M., Drake W.M. Response to Somatostatin Analog Therapy in a Patient With von Hippel-Lindau Disease and MultiplePancreatic Neuroendocrine Tumors. Pancreas. 2017;46(7):e57. [PubMed: 28697140]


16 of 18 2/11/19, 8:44 AM

154.

155.

156.

157.

158.

159.

160.

161.

162.163.

164.

165.

166.

167.

168.

169.170.

171.

172.

173.174.

175.176.

177.

Glasker S., Lonser R.R., Tran M.G., Ikejiri B., Butman J.A., Zeng W., Maxwell P.H., Zhuang Z., Oldfield E.H., Vortmeyer A.O.Effects of VHL deficiency on endolymphatic duct and sac. Cancer Res. 2005;65(23):10847–53. [PubMed: 16322231]Lonser R.R., Baggenstos M., Kim H.J., Butman J.A., Vortmeyer A.O. The vestibular aqueduct: site of origin of endolymphaticsac tumors. J Neurosurg. 2008;108(4):751–6. [PMC free article: PMC2770700] [PubMed: 18377255]Manski T.J., Heffner D.K., Glenn G.M., Patronas N.J., Pikus A.T., Katz D., Lebovics R., Sledjeski K., Choyke P.L., Zbar B.,Linehan W.M., Oldfield E.H. Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA.1997;277(18):1461–6. [PubMed: 9145719]Butman J.A., Kim H.J., Baggenstos M., Ammerman J.M., Dambrosia J., Patsalides A., Patronas N.J., Oldfield E.H., Lonser R.R.Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in von Hippel-Lindau disease. JAMA.2007;298(1):41–8. [PubMed: 17609489]Singh A.D., Shields C.L., Shields J.A. von Hippel-Lindau disease. Survey of Ophthalmology. 2001;46(2):117–42. [Review] [205refs] p. [PubMed: 11578646]Wilding A., Ingham S.L., Lalloo F., Clancy T., Huson S.M., Moran A., Evans D.G. Life expectancy in hereditary cancerpredisposing diseases: an observational study. J Med Genet. 2012;49(4):264–9. [PubMed: 22362873]Glasker S., Bender B.U., Apel T.W., Natt E., van Velthoven V., Scheremet R., Zentner J., Neumann H.P. The impact of moleculargenetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system. J Neurol NeurosurgPsychiatry. 1999;67(6):758–62. [PMC free article: PMC1736691] [PubMed: 10567493]Woodward E.R., Wall K., Forsyth J., Macdonald F., Maher E.R. VHL mutation analysis in patients with isolated central nervoussystem haemangioblastoma. Brain. 2007;130(Pt 3):836–42. [PubMed: 17264095]Maher E.R. Von Hippel-Lindau disease. Curr Mol Med. 2004;4(8):833–42. [PubMed: 15579030]Seizinger B.R., Rouleau G.A., Ozelius L.J., Lane A.H., Farmer G.E., Lamiell J.M., Haines J., Yuen J.W., Collins D., Majoor-Krakauer D., et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature.1988;332(6161):268–9. [PubMed: 2894613]Latif F., Tory K., Gnarra J., Yao M., Duh F.M., Orcutt M.L., Stackhouse T., Kuzmin I., Modi W., Geil L., Zbar B., Lerman M.Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317–20. [PubMed: 8493574]Kaelin W.G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nature Reviews. Cancer. 2002;2(9):673–82. [PubMed:12209156]Pause A., Lee S., Worrell R.A., Chen D.Y., Burgess W.H., Linehan W.M., Klausner R.D. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl AcadSci U S A. 1997;94(6):2156–61. [PMC free article: PMC20057] [PubMed: 9122164]Lonergan K.M., Iliopoulos O., Ohh M., Kamura T., Conaway R.C., Conaway J.W., Kaelin W.G. Jr. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C andCul2. Mol Cell Biol. 1998;18(2):732–41. [PMC free article: PMC108784] [PubMed: 9447969]Lisztwan J., Imbert G., Wirbelauer C., Gstaiger M., Krek W. The von Hippel-Lindau tumor suppressor protein is a component ofan E3 ubiquitin-protein ligase activity. Genes Dev. 1999;13(14):1822–33. [PMC free article: PMC316884] [PubMed: 10421634]Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721–32. [PubMed: 13130303]Iliopoulos O., Levy A.P., Jiang C., Kaelin W.G. Jr, Goldberg M.A. Negative regulation of hypoxia-inducible genes by the vonHippel-Lindau protein. Proc Natl Acad Sci U S A. 1996;93(20):10595–9. [PMC free article: PMC38198] [PubMed: 8855223]Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R.,Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature.1999;399(6733):271–5. [PubMed: 10353251]Krieg M., Haas R., Brauch H., Acker T., Flamme I., Plate K.H. Up-regulation of hypoxia-inducible factors HIF-1alpha andHIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.Oncogene. 2000;19(48):5435–43. [PubMed: 11114720]Frew I.J., Krek W. Multitasking by pVHL in tumour suppression. Curr Opin Cell Biol. 2007;19(6):685–90. [PubMed: 18006292]Young A.P., Schlisio S., Minamishima Y.A., Zhang Q., Li L., Grisanzio C., Signoretti S., Kaelin W.G. Jr. VHL loss actuates aHIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol. 2008;10(3):361–9. [PubMed: 18297059]Knudson A.G. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol. 1996;122(3):135–40. [PubMed: 8601560]Mandriota S.J., Turner K.J., Davies D.R., Murray P.G., Morgan N.V., Sowter H.M., Wykoff C.C., Maher E.R., Harris A.L.,Ratcliffe P.J., Maxwell P.H. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressorfunction in the nephron. Cancer Cell. 2002;1(5):459–68. [PubMed: 12124175]Ding Z., German P., Bai S., Feng Z., Gao M., Si W., Sobieski M.M., Stephan C.C., Mills G.B., Jonasch E. Agents That StabilizeMutated von Hippel-Lindau (VHL) Protein: Results of a High-Throughput Screen to Identify Compounds That Modulate VHLProteostasis. J Biomol Screen. 2012 Jun;17(5):572–80. [PMC free article: PMC3895461] [PubMed: 22357874]

Copyright © 2000-2019, MDText.com, Inc.


17 of 18 2/11/19, 8:44 AM

This electronic version has been made freely available under a Creative Commons (CC-BY-NC-ND) license. A copy of the license can be viewed at http://creativecommons.org/licenses/by-nc-nd/2.0/.

Bookshelf ID: NBK279124 PMID: 25905347


18 of 18 2/11/19, 8:44 AM

Documents

Von Hippel-Lindau Disease - Von Hippel-Lindau Disease...Figure 3. VHL disease associated renal cell carcinomas are of clear cell type (H&E stain). PHEOCHROMOCYTOMAS IN VHL SYNDROME